GlassScriptPhysician profile
Nathan Edward Williams
NPI 1093774234
$8,209.82
in general payments reported to CMS, 2019-2025
35 companies · $907 in 2025
The $907 reported for 2025 was more than what 83% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $810 · 2021: $1,940 · 2022: $1,162 · 2023: $1,322 · 2024: $1,254 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.95 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,611.60 | 2019-2025 | Piqray, Kisqali |
| Pfizer INC. | $774.72 | 2019-2025 | |
| Daiichi Sankyo INC. | $683.68 | 2021-2025 | Enhertu, Injectafer |
| Lilly USA, LLC | $617.12 | 2019-2025 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $516.87 | 2019-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $421.56 | 2020-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Amgen INC. | $292.83 | 2019-2022 | |
| Seagen INC. | $256.29 | 2020-2023 | Tukysa |
| Gilead Sciences, INC. | $250.36 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $224.76 | 2020-2021 | |
| Organon LLC | $213.56 | 2021-2022 | |
| Tactile Systems Technology INC | $212.62 | 2020-2023 | Entre Plus, Flexitouch Plus |
| Genentech USA, INC. | $170.08 | 2019-2023 | Perjeta, Phesgo |
| Puma Biotechnology, INC. | $168.88 | 2019-2024 | Nerlynx |
| Myriad Genetic Laboratories, INC. | $110.39 | 2020-2024 | Myrisk |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $80.02 | 2024 | Provenge |
| Tesaro, INC. | $71.89 | 2019 | |
| Eisai INC. | $68.68 | 2020-2022 | |
| Caris Mpi, INC. | $59.30 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $58.37 | 2024-2025 | Veozah |
| Accord Healthcare, INC. | $48.68 | 2025 | |
| Kyowa Kirin, INC. | $35.78 | 2019 | |
| Stemline Therapeutics INC. | $35.38 | 2023 | Orserdu |
| Abbvie INC. | $34.67 | 2025 | |
| Clovis Oncology, INC. | $25.99 | 2019 | |
| Tersera Therapeutics LLC | $22.19 | 2025 | Quzyttir |
| Janssen Biotech, INC. | $19.74 | 2019 | |
| Tempus Ai, INC | $19.73 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.53 | 2024 | Cosela |
| Coherus Oncology, INC. | $17.56 | 2021 | |
| Springworks Therapeutics, INC. | $14.47 | 2025 | Gomekli |
| Cashflow Solutions, LLC | $14.41 | 2023 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Boston Scientific Corporation | $13.85 | 2025 | Tria Firm |
| Bayer Healthcare Pharmaceuticals INC. | $13.10 | 2019 | |
| Stryker Corporation | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.